drugset / Trial / NCT05940116
A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HS-20117 as a monotherapy for participants with advanced solid tumors.
Timeline
- Start
- 2023-07-20
- Primary completion
- 2025-07-30
- Completion
- 2027-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-20117 | Monoclonal antibody | 400 mg | Intravenous |